nodes	percent_of_prediction	percent_of_DWPC	metapath
Esomeprazole—ATP4A—hematologic cancer	0.301	1	CbGaD
Esomeprazole—kidney cancer—Dexamethasone—hematologic cancer	0.102	0.29	CpDpCtD
Esomeprazole—kidney cancer—Betamethasone—hematologic cancer	0.102	0.29	CpDpCtD
Esomeprazole—prostate cancer—Dexamethasone—hematologic cancer	0.0737	0.21	CpDpCtD
Esomeprazole—prostate cancer—Betamethasone—hematologic cancer	0.0737	0.21	CpDpCtD
Esomeprazole—CYP2C19—Bortezomib—hematologic cancer	0.0129	0.069	CbGbCtD
Esomeprazole—CYP2C19—Thalidomide—hematologic cancer	0.0113	0.0601	CbGbCtD
Esomeprazole—CYP2C19—Teniposide—hematologic cancer	0.0107	0.0573	CbGbCtD
Esomeprazole—CYP3A4—Bexarotene—hematologic cancer	0.0102	0.0544	CbGbCtD
Esomeprazole—CYP2C19—Ifosfamide—hematologic cancer	0.00992	0.0529	CbGbCtD
Esomeprazole—CYP3A4—Busulfan—hematologic cancer	0.00948	0.0506	CbGbCtD
Esomeprazole—CYP3A4—Lomustine—hematologic cancer	0.00948	0.0506	CbGbCtD
Esomeprazole—CYP2C19—Imatinib—hematologic cancer	0.00947	0.0505	CbGbCtD
Esomeprazole—CYP3A4—Thiotepa—hematologic cancer	0.00845	0.0451	CbGbCtD
Esomeprazole—CYP3A4—Methoxsalen—hematologic cancer	0.00657	0.035	CbGbCtD
Esomeprazole—CYP3A4—Bortezomib—hematologic cancer	0.00625	0.0333	CbGbCtD
Esomeprazole—CYP2C19—Prednisone—hematologic cancer	0.00624	0.0333	CbGbCtD
Esomeprazole—CYP3A4—Daunorubicin—hematologic cancer	0.00598	0.0319	CbGbCtD
Esomeprazole—CYP3A4—Cytarabine—hematologic cancer	0.00527	0.0281	CbGbCtD
Esomeprazole—CYP3A4—Teniposide—hematologic cancer	0.00519	0.0277	CbGbCtD
Esomeprazole—CYP3A4—Ifosfamide—hematologic cancer	0.00479	0.0256	CbGbCtD
Esomeprazole—CYP3A4—Imatinib—hematologic cancer	0.00458	0.0244	CbGbCtD
Esomeprazole—CYP3A4—Ruxolitinib—hematologic cancer	0.00431	0.023	CbGbCtD
Esomeprazole—CYP3A4—Nilotinib—hematologic cancer	0.00416	0.0222	CbGbCtD
Esomeprazole—CYP3A4—Vinorelbine—hematologic cancer	0.00413	0.022	CbGbCtD
Esomeprazole—CYP2C19—Dexamethasone—hematologic cancer	0.0039	0.0208	CbGbCtD
Esomeprazole—CYP3A4—Triamcinolone—hematologic cancer	0.00377	0.0201	CbGbCtD
Esomeprazole—CYP3A4—Dasatinib—hematologic cancer	0.00368	0.0196	CbGbCtD
Esomeprazole—CYP3A4—Mitoxantrone—hematologic cancer	0.00363	0.0194	CbGbCtD
Esomeprazole—CYP3A4—Betamethasone—hematologic cancer	0.00324	0.0173	CbGbCtD
Esomeprazole—CYP3A4—Prednisolone—hematologic cancer	0.0032	0.017	CbGbCtD
Esomeprazole—CYP3A4—Prednisone—hematologic cancer	0.00302	0.0161	CbGbCtD
Esomeprazole—CYP3A4—Irinotecan—hematologic cancer	0.00286	0.0153	CbGbCtD
Esomeprazole—CYP3A4—Vinblastine—hematologic cancer	0.00254	0.0136	CbGbCtD
Esomeprazole—CYP3A4—Vincristine—hematologic cancer	0.0025	0.0133	CbGbCtD
Esomeprazole—CYP3A4—Etoposide—hematologic cancer	0.00229	0.0122	CbGbCtD
Esomeprazole—CYP3A4—Dexamethasone—hematologic cancer	0.00188	0.01	CbGbCtD
Esomeprazole—CYP3A4—Doxorubicin—hematologic cancer	0.00156	0.00833	CbGbCtD
Esomeprazole—Rabeprazole—ATP4A—hematologic cancer	0.000553	0.181	CrCbGaD
Esomeprazole—Pantoprazole—ATP4A—hematologic cancer	0.000553	0.181	CrCbGaD
Esomeprazole—ATP4B—Ion channel transport—FXYD6—hematologic cancer	0.00049	0.0295	CbGpPWpGaD
Esomeprazole—Omeprazole—ATP4A—hematologic cancer	0.000451	0.147	CrCbGaD
Esomeprazole—ATP4A—Ion channel transport—FXYD6—hematologic cancer	0.000437	0.0263	CbGpPWpGaD
Esomeprazole—Lansoprazole—ATP4A—hematologic cancer	0.000413	0.135	CrCbGaD
Esomeprazole—ATP4B—Ion channel transport—ATP1B1—hematologic cancer	0.000349	0.0211	CbGpPWpGaD
Esomeprazole—CYP3A4—Aflatoxin B1 metabolism—EPHX1—hematologic cancer	0.000318	0.0192	CbGpPWpGaD
Esomeprazole—ATP4A—Ion channel transport—ATP1B1—hematologic cancer	0.000311	0.0188	CbGpPWpGaD
Esomeprazole—ATP4B—Ion channel transport—ATP4A—hematologic cancer	0.000303	0.0183	CbGpPWpGaD
Esomeprazole—ATP4B—Ion channel transport—SGK1—hematologic cancer	0.000303	0.0183	CbGpPWpGaD
Esomeprazole—Omeprazole—ABCC3—hematologic cancer	0.000291	0.0949	CrCbGaD
Esomeprazole—ATP4A—Ion channel transport—SGK1—hematologic cancer	0.00027	0.0163	CbGpPWpGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—PER3—hematologic cancer	0.000263	0.0159	CbGpPWpGaD
Esomeprazole—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—hematologic cancer	0.00026	0.0157	CbGpPWpGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—CRY1—hematologic cancer	0.000224	0.0135	CbGpPWpGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—PER2—hematologic cancer	0.000224	0.0135	CbGpPWpGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—CRY2—hematologic cancer	0.000224	0.0135	CbGpPWpGaD
Esomeprazole—CYP3A4—Codeine and Morphine Metabolism—ABCC3—hematologic cancer	0.000184	0.0111	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000183	0.0111	CbGpPWpGaD
Esomeprazole—Rabeprazole—ABCG2—hematologic cancer	0.000173	0.0566	CrCbGaD
Esomeprazole—Pantoprazole—ABCG2—hematologic cancer	0.000173	0.0566	CrCbGaD
Esomeprazole—CYP3A4—Codeine and Morphine Metabolism—UGT1A1—hematologic cancer	0.000173	0.0104	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000171	0.0103	CbGpPWpGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—PER1—hematologic cancer	0.000169	0.0102	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000163	0.00986	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000152	0.00916	CbGpPWpGaD
Esomeprazole—Omeprazole—ABCG2—hematologic cancer	0.000141	0.0461	CrCbGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000139	0.00838	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000129	0.00779	CbGpPWpGaD
Esomeprazole—Lansoprazole—ABCG2—hematologic cancer	0.000129	0.0422	CrCbGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000124	0.00747	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000122	0.00733	CbGpPWpGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—ARNTL—hematologic cancer	0.000121	0.00728	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000115	0.00695	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000115	0.00695	CbGpPWpGaD
Esomeprazole—CYP3A4—Irinotecan Pathway—UGT1A1—hematologic cancer	0.000111	0.00667	CbGpPWpGaD
Esomeprazole—CYP3A4—Farnesoid X Receptor  Pathway—NR0B2—hematologic cancer	0.000108	0.00653	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000108	0.00653	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.000105	0.00635	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.000105	0.00635	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.000105	0.00635	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000103	0.00619	CbGpPWpGaD
Esomeprazole—CYP3A4—Aflatoxin B1 metabolism—GSTM1—hematologic cancer	0.000101	0.0061	CbGpPWpGaD
Esomeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—ABCC3—hematologic cancer	0.000101	0.00609	CbGpPWpGaD
Esomeprazole—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC3—hematologic cancer	0.000101	0.00607	CbGpPWpGaD
Esomeprazole—CYP3A4—Irinotecan Pathway—ABCG2—hematologic cancer	9.58e-05	0.00578	CbGpPWpGaD
Esomeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—UGT1A1—hematologic cancer	9.49e-05	0.00572	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	9.49e-05	0.00572	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—SGK1—hematologic cancer	9.39e-05	0.00566	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ANXA2—hematologic cancer	9.39e-05	0.00566	CbGpPWpGaD
Esomeprazole—CYP3A4—Codeine and Morphine Metabolism—ABCB1—hematologic cancer	9.36e-05	0.00564	CbGpPWpGaD
Esomeprazole—CYP3A4—Estrogen metabolism—UGT1A1—hematologic cancer	9.04e-05	0.00545	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	8.45e-05	0.0051	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ABCC3—hematologic cancer	8.33e-05	0.00502	CbGpPWpGaD
Esomeprazole—CYP3A4—Farnesoid X Receptor  Pathway—FGF19—hematologic cancer	8.14e-05	0.00491	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	7.62e-05	0.00459	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ABCC3—hematologic cancer	7.42e-05	0.00448	CbGpPWpGaD
Esomeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—SMC1A—hematologic cancer	7.41e-05	0.00447	CbGpPWpGaD
Esomeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—hematologic cancer	7.31e-05	0.00441	CbGpPWpGaD
Esomeprazole—Pantoprazole—ABCB1—hematologic cancer	7.21e-05	0.0235	CrCbGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—NUP98—hematologic cancer	7.19e-05	0.00433	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ADCY7—hematologic cancer	6.98e-05	0.00421	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—NUP214—hematologic cancer	6.93e-05	0.00418	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	6.79e-05	0.00409	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ABCG2—hematologic cancer	6.79e-05	0.00409	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—NUP98—hematologic cancer	6.41e-05	0.00386	CbGpPWpGaD
Esomeprazole—CYP2C19—Arachidonic acid metabolism—ALOX5—hematologic cancer	6.29e-05	0.0038	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ADCY7—hematologic cancer	6.22e-05	0.00375	CbGpPWpGaD
Esomeprazole—CYP3A4—Estrogen metabolism—NQO1—hematologic cancer	6.2e-05	0.00374	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—NUP214—hematologic cancer	6.18e-05	0.00372	CbGpPWpGaD
Esomeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—HSP90AA1—hematologic cancer	6.11e-05	0.00369	CbGpPWpGaD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC3—hematologic cancer	6.07e-05	0.00366	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—TFRC—hematologic cancer	6.05e-05	0.00365	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ABCG2—hematologic cancer	6.05e-05	0.00365	CbGpPWpGaD
Esomeprazole—Omeprazole—ABCB1—hematologic cancer	5.88e-05	0.0192	CrCbGaD
Esomeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—hematologic cancer	5.78e-05	0.00349	CbGpPWpGaD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—UGT1A1—hematologic cancer	5.71e-05	0.00344	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—TFRC—hematologic cancer	5.39e-05	0.00325	CbGpPWpGaD
Esomeprazole—Lansoprazole—ABCB1—hematologic cancer	5.38e-05	0.0176	CrCbGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—FOXO1—hematologic cancer	5.25e-05	0.00317	CbGpPWpGaD
Esomeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—hematologic cancer	5.13e-05	0.0031	CbGpPWpGaD
Esomeprazole—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—hematologic cancer	5.12e-05	0.00309	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—CYCS—hematologic cancer	5.08e-05	0.00306	CbGpPWpGaD
Esomeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	4.86e-05	0.00293	CbGpPWpGaD
Esomeprazole—CYP3A4—Estrogen metabolism—GSTM1—hematologic cancer	4.75e-05	0.00286	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—CYCS—hematologic cancer	4.53e-05	0.00273	CbGpPWpGaD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—hematologic cancer	4.45e-05	0.00269	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ABCB1—hematologic cancer	4.24e-05	0.00255	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—SLC35B2—hematologic cancer	4.08e-05	0.00246	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—EPHX1—hematologic cancer	4.02e-05	0.00243	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.78e-05	0.00228	CbGpPWpGaD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—HSP90AA1—hematologic cancer	3.68e-05	0.00222	CbGpPWpGaD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—hematologic cancer	3.09e-05	0.00186	CbGpPWpGaD
Esomeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—hematologic cancer	2.94e-05	0.00177	CbGpPWpGaD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	2.92e-05	0.00176	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.83e-05	0.00171	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ALB—hematologic cancer	2.65e-05	0.0016	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GSTO1—hematologic cancer	2.63e-05	0.00158	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTO1—hematologic cancer	2.59e-05	0.00156	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.52e-05	0.00152	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—UGT1A1—hematologic cancer	2.47e-05	0.00149	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—SLC35B2—hematologic cancer	2.45e-05	0.00148	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—UGT1A1—hematologic cancer	2.44e-05	0.00147	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PHYH—hematologic cancer	2.43e-05	0.00147	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—EPHX1—hematologic cancer	2.42e-05	0.00146	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ALB—hematologic cancer	2.36e-05	0.00142	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—SMPD3—hematologic cancer	2.22e-05	0.00134	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—MTR—hematologic cancer	2.14e-05	0.00129	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GSTT1—hematologic cancer	2.04e-05	0.00123	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GSTO1—hematologic cancer	1.58e-05	0.000953	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	1.57e-05	0.000944	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTO1—hematologic cancer	1.56e-05	0.00094	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—UGT1A1—hematologic cancer	1.49e-05	0.000896	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—UGT1A1—hematologic cancer	1.47e-05	0.000884	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GSTP1—hematologic cancer	1.41e-05	0.000852	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTP1—hematologic cancer	1.39e-05	0.00084	CbGpPWpGaD
Esomeprazole—CYP3A4—Tryptophan metabolism—MDM2—hematologic cancer	1.31e-05	0.000791	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GSTM1—hematologic cancer	1.3e-05	0.000783	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—MTR—hematologic cancer	1.29e-05	0.000777	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTM1—hematologic cancer	1.28e-05	0.000772	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	1.28e-05	0.00077	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GSTT1—hematologic cancer	1.23e-05	0.000739	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	1.12e-05	0.000673	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—FTCD—hematologic cancer	1.08e-05	0.000653	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PHYH—hematologic cancer	1.08e-05	0.000653	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GMPS—hematologic cancer	1.08e-05	0.000653	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	1.07e-05	0.000646	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	1.02e-05	0.000615	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	1.01e-05	0.000609	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—SMPD3—hematologic cancer	9.9e-06	0.000597	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	9.88e-06	0.000596	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	9.23e-06	0.000557	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	8.99e-06	0.000542	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ASNS—hematologic cancer	8.65e-06	0.000522	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—DCK—hematologic cancer	8.65e-06	0.000522	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—B3GAT1—hematologic cancer	8.65e-06	0.000522	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	8.49e-06	0.000512	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	8.46e-06	0.00051	CbGpPWpGaD
Esomeprazole—Vision blurred—Methotrexate—hematologic cancer	8.44e-06	6.02e-05	CcSEcCtD
Esomeprazole—Mental disorder—Epirubicin—hematologic cancer	8.44e-06	6.01e-05	CcSEcCtD
Esomeprazole—Erythema multiforme—Doxorubicin—hematologic cancer	8.43e-06	6.01e-05	CcSEcCtD
Esomeprazole—Rash—Cisplatin—hematologic cancer	8.4e-06	5.99e-05	CcSEcCtD
Esomeprazole—Dermatitis—Cisplatin—hematologic cancer	8.39e-06	5.98e-05	CcSEcCtD
Esomeprazole—Malnutrition—Epirubicin—hematologic cancer	8.38e-06	5.98e-05	CcSEcCtD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	8.38e-06	0.000505	CbGpPWpGaD
Esomeprazole—Diarrhoea—Etoposide—hematologic cancer	8.35e-06	5.95e-05	CcSEcCtD
Esomeprazole—Anorexia—Prednisone—hematologic cancer	8.34e-06	5.94e-05	CcSEcCtD
Esomeprazole—Eye disorder—Doxorubicin—hematologic cancer	8.33e-06	5.94e-05	CcSEcCtD
Esomeprazole—Ill-defined disorder—Methotrexate—hematologic cancer	8.31e-06	5.92e-05	CcSEcCtD
Esomeprazole—Tinnitus—Doxorubicin—hematologic cancer	8.31e-06	5.92e-05	CcSEcCtD
Esomeprazole—Anaemia—Methotrexate—hematologic cancer	8.28e-06	5.9e-05	CcSEcCtD
Esomeprazole—Feeling abnormal—Betamethasone—hematologic cancer	8.28e-06	5.9e-05	CcSEcCtD
Esomeprazole—Feeling abnormal—Dexamethasone—hematologic cancer	8.28e-06	5.9e-05	CcSEcCtD
Esomeprazole—Flushing—Doxorubicin—hematologic cancer	8.27e-06	5.89e-05	CcSEcCtD
Esomeprazole—Flatulence—Epirubicin—hematologic cancer	8.26e-06	5.89e-05	CcSEcCtD
Esomeprazole—Tension—Epirubicin—hematologic cancer	8.23e-06	5.86e-05	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Betamethasone—hematologic cancer	8.21e-06	5.85e-05	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Dexamethasone—hematologic cancer	8.21e-06	5.85e-05	CcSEcCtD
Esomeprazole—Dysgeusia—Epirubicin—hematologic cancer	8.21e-06	5.85e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—HDC—hematologic cancer	8.2e-06	0.000495	CbGpPWpGaD
Esomeprazole—Hypersensitivity—Triamcinolone—hematologic cancer	8.16e-06	5.81e-05	CcSEcCtD
Esomeprazole—Nervousness—Epirubicin—hematologic cancer	8.14e-06	5.8e-05	CcSEcCtD
Esomeprazole—Back pain—Epirubicin—hematologic cancer	8.11e-06	5.78e-05	CcSEcCtD
Esomeprazole—Malaise—Methotrexate—hematologic cancer	8.08e-06	5.76e-05	CcSEcCtD
Esomeprazole—Dizziness—Etoposide—hematologic cancer	8.07e-06	5.75e-05	CcSEcCtD
Esomeprazole—Muscle spasms—Epirubicin—hematologic cancer	8.06e-06	5.74e-05	CcSEcCtD
Esomeprazole—Immune system disorder—Doxorubicin—hematologic cancer	8.05e-06	5.74e-05	CcSEcCtD
Esomeprazole—Vertigo—Methotrexate—hematologic cancer	8.05e-06	5.74e-05	CcSEcCtD
Esomeprazole—Mediastinal disorder—Doxorubicin—hematologic cancer	8.03e-06	5.72e-05	CcSEcCtD
Esomeprazole—Leukopenia—Methotrexate—hematologic cancer	8.02e-06	5.72e-05	CcSEcCtD
Esomeprazole—Chills—Doxorubicin—hematologic cancer	8e-06	5.7e-05	CcSEcCtD
Esomeprazole—Urticaria—Betamethasone—hematologic cancer	7.98e-06	5.69e-05	CcSEcCtD
Esomeprazole—Urticaria—Dexamethasone—hematologic cancer	7.98e-06	5.69e-05	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Prednisone—hematologic cancer	7.97e-06	5.68e-05	CcSEcCtD
Esomeprazole—Dizziness—Prednisolone—hematologic cancer	7.96e-06	5.67e-05	CcSEcCtD
Esomeprazole—Asthenia—Triamcinolone—hematologic cancer	7.94e-06	5.66e-05	CcSEcCtD
Esomeprazole—Body temperature increased—Betamethasone—hematologic cancer	7.94e-06	5.66e-05	CcSEcCtD
Esomeprazole—Abdominal pain—Betamethasone—hematologic cancer	7.94e-06	5.66e-05	CcSEcCtD
Esomeprazole—Abdominal pain—Dexamethasone—hematologic cancer	7.94e-06	5.66e-05	CcSEcCtD
Esomeprazole—Body temperature increased—Dexamethasone—hematologic cancer	7.94e-06	5.66e-05	CcSEcCtD
Esomeprazole—Nausea—Cisplatin—hematologic cancer	7.91e-06	5.64e-05	CcSEcCtD
Esomeprazole—Insomnia—Prednisone—hematologic cancer	7.91e-06	5.64e-05	CcSEcCtD
Esomeprazole—Vision blurred—Epirubicin—hematologic cancer	7.9e-06	5.63e-05	CcSEcCtD
Esomeprazole—Alopecia—Doxorubicin—hematologic cancer	7.87e-06	5.61e-05	CcSEcCtD
Esomeprazole—Paraesthesia—Prednisone—hematologic cancer	7.86e-06	5.6e-05	CcSEcCtD
Esomeprazole—Pruritus—Triamcinolone—hematologic cancer	7.83e-06	5.58e-05	CcSEcCtD
Esomeprazole—Cough—Methotrexate—hematologic cancer	7.82e-06	5.57e-05	CcSEcCtD
Esomeprazole—Mental disorder—Doxorubicin—hematologic cancer	7.81e-06	5.56e-05	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	7.81e-06	0.000471	CbGpPWpGaD
Esomeprazole—Ill-defined disorder—Epirubicin—hematologic cancer	7.78e-06	5.54e-05	CcSEcCtD
Esomeprazole—Vomiting—Etoposide—hematologic cancer	7.76e-06	5.53e-05	CcSEcCtD
Esomeprazole—Malnutrition—Doxorubicin—hematologic cancer	7.76e-06	5.53e-05	CcSEcCtD
Esomeprazole—Anaemia—Epirubicin—hematologic cancer	7.75e-06	5.52e-05	CcSEcCtD
Esomeprazole—Agitation—Epirubicin—hematologic cancer	7.7e-06	5.49e-05	CcSEcCtD
Esomeprazole—Dyspepsia—Prednisone—hematologic cancer	7.7e-06	5.49e-05	CcSEcCtD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	7.7e-06	0.000464	CbGpPWpGaD
Esomeprazole—Rash—Etoposide—hematologic cancer	7.7e-06	5.49e-05	CcSEcCtD
Esomeprazole—Dermatitis—Etoposide—hematologic cancer	7.69e-06	5.48e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	7.65e-06	0.000461	CbGpPWpGaD
Esomeprazole—Headache—Etoposide—hematologic cancer	7.65e-06	5.45e-05	CcSEcCtD
Esomeprazole—Flatulence—Doxorubicin—hematologic cancer	7.64e-06	5.45e-05	CcSEcCtD
Esomeprazole—Arthralgia—Methotrexate—hematologic cancer	7.63e-06	5.44e-05	CcSEcCtD
Esomeprazole—Myalgia—Methotrexate—hematologic cancer	7.63e-06	5.44e-05	CcSEcCtD
Esomeprazole—Chest pain—Methotrexate—hematologic cancer	7.63e-06	5.44e-05	CcSEcCtD
Esomeprazole—Tension—Doxorubicin—hematologic cancer	7.61e-06	5.43e-05	CcSEcCtD
Esomeprazole—Decreased appetite—Prednisone—hematologic cancer	7.6e-06	5.42e-05	CcSEcCtD
Esomeprazole—Dysgeusia—Doxorubicin—hematologic cancer	7.6e-06	5.41e-05	CcSEcCtD
Esomeprazole—Rash—Prednisolone—hematologic cancer	7.59e-06	5.41e-05	CcSEcCtD
Esomeprazole—Dermatitis—Prednisolone—hematologic cancer	7.58e-06	5.41e-05	CcSEcCtD
Esomeprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	7.57e-06	5.4e-05	CcSEcCtD
Esomeprazole—Malaise—Epirubicin—hematologic cancer	7.56e-06	5.39e-05	CcSEcCtD
Esomeprazole—Fatigue—Prednisone—hematologic cancer	7.54e-06	5.38e-05	CcSEcCtD
Esomeprazole—Headache—Prednisolone—hematologic cancer	7.54e-06	5.38e-05	CcSEcCtD
Esomeprazole—Discomfort—Methotrexate—hematologic cancer	7.54e-06	5.37e-05	CcSEcCtD
Esomeprazole—Nervousness—Doxorubicin—hematologic cancer	7.53e-06	5.37e-05	CcSEcCtD
Esomeprazole—Vertigo—Epirubicin—hematologic cancer	7.53e-06	5.37e-05	CcSEcCtD
Esomeprazole—Leukopenia—Epirubicin—hematologic cancer	7.5e-06	5.35e-05	CcSEcCtD
Esomeprazole—Back pain—Doxorubicin—hematologic cancer	7.5e-06	5.35e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—CDA—hematologic cancer	7.5e-06	0.000452	CbGpPWpGaD
Esomeprazole—Constipation—Prednisone—hematologic cancer	7.48e-06	5.33e-05	CcSEcCtD
Esomeprazole—Muscle spasms—Doxorubicin—hematologic cancer	7.46e-06	5.32e-05	CcSEcCtD
Esomeprazole—Palpitations—Epirubicin—hematologic cancer	7.41e-06	5.28e-05	CcSEcCtD
Esomeprazole—Confusional state—Methotrexate—hematologic cancer	7.37e-06	5.25e-05	CcSEcCtD
Esomeprazole—Dizziness—Triamcinolone—hematologic cancer	7.32e-06	5.22e-05	CcSEcCtD
Esomeprazole—Cough—Epirubicin—hematologic cancer	7.32e-06	5.21e-05	CcSEcCtD
Esomeprazole—Anaphylactic shock—Methotrexate—hematologic cancer	7.31e-06	5.21e-05	CcSEcCtD
Esomeprazole—Vision blurred—Doxorubicin—hematologic cancer	7.31e-06	5.21e-05	CcSEcCtD
Esomeprazole—Infection—Methotrexate—hematologic cancer	7.26e-06	5.18e-05	CcSEcCtD
Esomeprazole—Nausea—Etoposide—hematologic cancer	7.25e-06	5.17e-05	CcSEcCtD
Esomeprazole—Hypertension—Epirubicin—hematologic cancer	7.24e-06	5.16e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—PC—hematologic cancer	7.22e-06	0.000435	CbGpPWpGaD
Esomeprazole—Feeling abnormal—Prednisone—hematologic cancer	7.21e-06	5.14e-05	CcSEcCtD
Esomeprazole—Asthenia—Betamethasone—hematologic cancer	7.21e-06	5.14e-05	CcSEcCtD
Esomeprazole—Asthenia—Dexamethasone—hematologic cancer	7.21e-06	5.14e-05	CcSEcCtD
Esomeprazole—Ill-defined disorder—Doxorubicin—hematologic cancer	7.2e-06	5.13e-05	CcSEcCtD
Esomeprazole—Nervous system disorder—Methotrexate—hematologic cancer	7.17e-06	5.11e-05	CcSEcCtD
Esomeprazole—Anaemia—Doxorubicin—hematologic cancer	7.17e-06	5.11e-05	CcSEcCtD
Esomeprazole—Thrombocytopenia—Methotrexate—hematologic cancer	7.16e-06	5.1e-05	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Prednisone—hematologic cancer	7.15e-06	5.1e-05	CcSEcCtD
Esomeprazole—Nausea—Prednisolone—hematologic cancer	7.15e-06	5.1e-05	CcSEcCtD
Esomeprazole—Arthralgia—Epirubicin—hematologic cancer	7.14e-06	5.09e-05	CcSEcCtD
Esomeprazole—Myalgia—Epirubicin—hematologic cancer	7.14e-06	5.09e-05	CcSEcCtD
Esomeprazole—Chest pain—Epirubicin—hematologic cancer	7.14e-06	5.09e-05	CcSEcCtD
Esomeprazole—Agitation—Doxorubicin—hematologic cancer	7.13e-06	5.08e-05	CcSEcCtD
Esomeprazole—Anxiety—Epirubicin—hematologic cancer	7.11e-06	5.07e-05	CcSEcCtD
Esomeprazole—Pruritus—Betamethasone—hematologic cancer	7.11e-06	5.07e-05	CcSEcCtD
Esomeprazole—Pruritus—Dexamethasone—hematologic cancer	7.11e-06	5.07e-05	CcSEcCtD
Esomeprazole—Skin disorder—Methotrexate—hematologic cancer	7.1e-06	5.06e-05	CcSEcCtD
Esomeprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	7.09e-06	5.05e-05	CcSEcCtD
Esomeprazole—Hyperhidrosis—Methotrexate—hematologic cancer	7.07e-06	5.04e-05	CcSEcCtD
Esomeprazole—Discomfort—Epirubicin—hematologic cancer	7.05e-06	5.03e-05	CcSEcCtD
Esomeprazole—Vomiting—Triamcinolone—hematologic cancer	7.04e-06	5.02e-05	CcSEcCtD
Esomeprazole—Malaise—Doxorubicin—hematologic cancer	7e-06	4.99e-05	CcSEcCtD
Esomeprazole—Rash—Triamcinolone—hematologic cancer	6.98e-06	4.98e-05	CcSEcCtD
Esomeprazole—Dry mouth—Epirubicin—hematologic cancer	6.98e-06	4.98e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—GBA—hematologic cancer	6.97e-06	0.000421	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—SLC35B2—hematologic cancer	6.97e-06	0.000421	CbGpPWpGaD
Esomeprazole—Dermatitis—Triamcinolone—hematologic cancer	6.97e-06	4.97e-05	CcSEcCtD
Esomeprazole—Vertigo—Doxorubicin—hematologic cancer	6.97e-06	4.97e-05	CcSEcCtD
Esomeprazole—Anorexia—Methotrexate—hematologic cancer	6.97e-06	4.97e-05	CcSEcCtD
Esomeprazole—Urticaria—Prednisone—hematologic cancer	6.95e-06	4.95e-05	CcSEcCtD
Esomeprazole—Leukopenia—Doxorubicin—hematologic cancer	6.94e-06	4.95e-05	CcSEcCtD
Esomeprazole—Headache—Triamcinolone—hematologic cancer	6.94e-06	4.94e-05	CcSEcCtD
Esomeprazole—Body temperature increased—Prednisone—hematologic cancer	6.92e-06	4.93e-05	CcSEcCtD
Esomeprazole—Abdominal pain—Prednisone—hematologic cancer	6.92e-06	4.93e-05	CcSEcCtD
Esomeprazole—Confusional state—Epirubicin—hematologic cancer	6.9e-06	4.92e-05	CcSEcCtD
Esomeprazole—Diarrhoea—Betamethasone—hematologic cancer	6.87e-06	4.9e-05	CcSEcCtD
Esomeprazole—Diarrhoea—Dexamethasone—hematologic cancer	6.87e-06	4.9e-05	CcSEcCtD
Esomeprazole—Palpitations—Doxorubicin—hematologic cancer	6.85e-06	4.89e-05	CcSEcCtD
Esomeprazole—Anaphylactic shock—Epirubicin—hematologic cancer	6.84e-06	4.88e-05	CcSEcCtD
Esomeprazole—Infection—Epirubicin—hematologic cancer	6.8e-06	4.84e-05	CcSEcCtD
Esomeprazole—Cough—Doxorubicin—hematologic cancer	6.77e-06	4.82e-05	CcSEcCtD
Esomeprazole—Shock—Epirubicin—hematologic cancer	6.73e-06	4.8e-05	CcSEcCtD
Esomeprazole—Nervous system disorder—Epirubicin—hematologic cancer	6.71e-06	4.78e-05	CcSEcCtD
Esomeprazole—Thrombocytopenia—Epirubicin—hematologic cancer	6.7e-06	4.77e-05	CcSEcCtD
Esomeprazole—Hypertension—Doxorubicin—hematologic cancer	6.7e-06	4.77e-05	CcSEcCtD
Esomeprazole—Tachycardia—Epirubicin—hematologic cancer	6.68e-06	4.76e-05	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Methotrexate—hematologic cancer	6.66e-06	4.75e-05	CcSEcCtD
Esomeprazole—Skin disorder—Epirubicin—hematologic cancer	6.65e-06	4.74e-05	CcSEcCtD
Esomeprazole—Dizziness—Dexamethasone—hematologic cancer	6.64e-06	4.73e-05	CcSEcCtD
Esomeprazole—Dizziness—Betamethasone—hematologic cancer	6.64e-06	4.73e-05	CcSEcCtD
Esomeprazole—Hyperhidrosis—Epirubicin—hematologic cancer	6.61e-06	4.71e-05	CcSEcCtD
Esomeprazole—Insomnia—Methotrexate—hematologic cancer	6.61e-06	4.71e-05	CcSEcCtD
Esomeprazole—Myalgia—Doxorubicin—hematologic cancer	6.6e-06	4.71e-05	CcSEcCtD
Esomeprazole—Chest pain—Doxorubicin—hematologic cancer	6.6e-06	4.71e-05	CcSEcCtD
Esomeprazole—Arthralgia—Doxorubicin—hematologic cancer	6.6e-06	4.71e-05	CcSEcCtD
Esomeprazole—Anxiety—Doxorubicin—hematologic cancer	6.58e-06	4.69e-05	CcSEcCtD
Esomeprazole—Nausea—Triamcinolone—hematologic cancer	6.58e-06	4.69e-05	CcSEcCtD
Esomeprazole—Paraesthesia—Methotrexate—hematologic cancer	6.56e-06	4.68e-05	CcSEcCtD
Esomeprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	6.56e-06	4.67e-05	CcSEcCtD
Esomeprazole—Discomfort—Doxorubicin—hematologic cancer	6.52e-06	4.65e-05	CcSEcCtD
Esomeprazole—Anorexia—Epirubicin—hematologic cancer	6.52e-06	4.65e-05	CcSEcCtD
Esomeprazole—Dyspnoea—Methotrexate—hematologic cancer	6.52e-06	4.65e-05	CcSEcCtD
Esomeprazole—CYP3A4—Metabolism—PHYH—hematologic cancer	6.51e-06	0.000392	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GMPS—hematologic cancer	6.51e-06	0.000392	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—FTCD—hematologic cancer	6.51e-06	0.000392	CbGpPWpGaD
Esomeprazole—Somnolence—Methotrexate—hematologic cancer	6.5e-06	4.63e-05	CcSEcCtD
Esomeprazole—Dry mouth—Doxorubicin—hematologic cancer	6.46e-06	4.6e-05	CcSEcCtD
Esomeprazole—Hypersensitivity—Prednisone—hematologic cancer	6.45e-06	4.59e-05	CcSEcCtD
Esomeprazole—Dyspepsia—Methotrexate—hematologic cancer	6.44e-06	4.59e-05	CcSEcCtD
Esomeprazole—Vomiting—Dexamethasone—hematologic cancer	6.39e-06	4.55e-05	CcSEcCtD
Esomeprazole—Vomiting—Betamethasone—hematologic cancer	6.39e-06	4.55e-05	CcSEcCtD
Esomeprazole—Confusional state—Doxorubicin—hematologic cancer	6.38e-06	4.55e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—MTAP—hematologic cancer	6.38e-06	0.000385	CbGpPWpGaD
Esomeprazole—Decreased appetite—Methotrexate—hematologic cancer	6.36e-06	4.53e-05	CcSEcCtD
Esomeprazole—Rash—Betamethasone—hematologic cancer	6.33e-06	4.51e-05	CcSEcCtD
Esomeprazole—Rash—Dexamethasone—hematologic cancer	6.33e-06	4.51e-05	CcSEcCtD
Esomeprazole—Anaphylactic shock—Doxorubicin—hematologic cancer	6.33e-06	4.51e-05	CcSEcCtD
Esomeprazole—Dermatitis—Dexamethasone—hematologic cancer	6.33e-06	4.51e-05	CcSEcCtD
Esomeprazole—Dermatitis—Betamethasone—hematologic cancer	6.33e-06	4.51e-05	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Methotrexate—hematologic cancer	6.31e-06	4.5e-05	CcSEcCtD
Esomeprazole—Fatigue—Methotrexate—hematologic cancer	6.3e-06	4.49e-05	CcSEcCtD
Esomeprazole—Headache—Betamethasone—hematologic cancer	6.29e-06	4.49e-05	CcSEcCtD
Esomeprazole—Headache—Dexamethasone—hematologic cancer	6.29e-06	4.49e-05	CcSEcCtD
Esomeprazole—Infection—Doxorubicin—hematologic cancer	6.29e-06	4.48e-05	CcSEcCtD
Esomeprazole—Asthenia—Prednisone—hematologic cancer	6.28e-06	4.47e-05	CcSEcCtD
Esomeprazole—Pain—Methotrexate—hematologic cancer	6.25e-06	4.46e-05	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Epirubicin—hematologic cancer	6.23e-06	4.44e-05	CcSEcCtD
Esomeprazole—Shock—Doxorubicin—hematologic cancer	6.23e-06	4.44e-05	CcSEcCtD
Esomeprazole—Nervous system disorder—Doxorubicin—hematologic cancer	6.21e-06	4.43e-05	CcSEcCtD
Esomeprazole—Thrombocytopenia—Doxorubicin—hematologic cancer	6.2e-06	4.42e-05	CcSEcCtD
Esomeprazole—Pruritus—Prednisone—hematologic cancer	6.19e-06	4.41e-05	CcSEcCtD
Esomeprazole—Insomnia—Epirubicin—hematologic cancer	6.19e-06	4.41e-05	CcSEcCtD
Esomeprazole—Tachycardia—Doxorubicin—hematologic cancer	6.18e-06	4.4e-05	CcSEcCtD
Esomeprazole—Skin disorder—Doxorubicin—hematologic cancer	6.15e-06	4.38e-05	CcSEcCtD
Esomeprazole—Paraesthesia—Epirubicin—hematologic cancer	6.14e-06	4.38e-05	CcSEcCtD
Esomeprazole—Hyperhidrosis—Doxorubicin—hematologic cancer	6.12e-06	4.36e-05	CcSEcCtD
Esomeprazole—Dyspnoea—Epirubicin—hematologic cancer	6.1e-06	4.35e-05	CcSEcCtD
Esomeprazole—Somnolence—Epirubicin—hematologic cancer	6.08e-06	4.34e-05	CcSEcCtD
Esomeprazole—Anorexia—Doxorubicin—hematologic cancer	6.03e-06	4.3e-05	CcSEcCtD
Esomeprazole—Feeling abnormal—Methotrexate—hematologic cancer	6.02e-06	4.29e-05	CcSEcCtD
Esomeprazole—Dyspepsia—Epirubicin—hematologic cancer	6.02e-06	4.29e-05	CcSEcCtD
Esomeprazole—Diarrhoea—Prednisone—hematologic cancer	5.99e-06	4.27e-05	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Methotrexate—hematologic cancer	5.98e-06	4.26e-05	CcSEcCtD
Esomeprazole—Nausea—Betamethasone—hematologic cancer	5.97e-06	4.25e-05	CcSEcCtD
Esomeprazole—Nausea—Dexamethasone—hematologic cancer	5.97e-06	4.25e-05	CcSEcCtD
Esomeprazole—CYP3A4—Metabolism—SMPD3—hematologic cancer	5.95e-06	0.000359	CbGpPWpGaD
Esomeprazole—Decreased appetite—Epirubicin—hematologic cancer	5.95e-06	4.24e-05	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.91e-06	4.21e-05	CcSEcCtD
Esomeprazole—Fatigue—Epirubicin—hematologic cancer	5.9e-06	4.2e-05	CcSEcCtD
Esomeprazole—Pain—Epirubicin—hematologic cancer	5.85e-06	4.17e-05	CcSEcCtD
Esomeprazole—Constipation—Epirubicin—hematologic cancer	5.85e-06	4.17e-05	CcSEcCtD
Esomeprazole—Urticaria—Methotrexate—hematologic cancer	5.81e-06	4.14e-05	CcSEcCtD
Esomeprazole—Dizziness—Prednisone—hematologic cancer	5.78e-06	4.12e-05	CcSEcCtD
Esomeprazole—Abdominal pain—Methotrexate—hematologic cancer	5.78e-06	4.12e-05	CcSEcCtD
Esomeprazole—Body temperature increased—Methotrexate—hematologic cancer	5.78e-06	4.12e-05	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	5.77e-06	4.11e-05	CcSEcCtD
Esomeprazole—Insomnia—Doxorubicin—hematologic cancer	5.73e-06	4.08e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—FHL2—hematologic cancer	5.69e-06	0.000343	CbGpPWpGaD
Esomeprazole—Paraesthesia—Doxorubicin—hematologic cancer	5.68e-06	4.05e-05	CcSEcCtD
Esomeprazole—Dyspnoea—Doxorubicin—hematologic cancer	5.64e-06	4.02e-05	CcSEcCtD
Esomeprazole—Feeling abnormal—Epirubicin—hematologic cancer	5.64e-06	4.02e-05	CcSEcCtD
Esomeprazole—Somnolence—Doxorubicin—hematologic cancer	5.63e-06	4.01e-05	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Epirubicin—hematologic cancer	5.59e-06	3.99e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—AGRN—hematologic cancer	5.58e-06	0.000336	CbGpPWpGaD
Esomeprazole—Dyspepsia—Doxorubicin—hematologic cancer	5.57e-06	3.97e-05	CcSEcCtD
Esomeprazole—Vomiting—Prednisone—hematologic cancer	5.56e-06	3.96e-05	CcSEcCtD
Esomeprazole—Rash—Prednisone—hematologic cancer	5.52e-06	3.93e-05	CcSEcCtD
Esomeprazole—Dermatitis—Prednisone—hematologic cancer	5.51e-06	3.93e-05	CcSEcCtD
Esomeprazole—Decreased appetite—Doxorubicin—hematologic cancer	5.5e-06	3.92e-05	CcSEcCtD
Esomeprazole—Headache—Prednisone—hematologic cancer	5.48e-06	3.91e-05	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Doxorubicin—hematologic cancer	5.47e-06	3.9e-05	CcSEcCtD
Esomeprazole—Fatigue—Doxorubicin—hematologic cancer	5.46e-06	3.89e-05	CcSEcCtD
Esomeprazole—Urticaria—Epirubicin—hematologic cancer	5.44e-06	3.87e-05	CcSEcCtD
Esomeprazole—Pain—Doxorubicin—hematologic cancer	5.41e-06	3.86e-05	CcSEcCtD
Esomeprazole—Constipation—Doxorubicin—hematologic cancer	5.41e-06	3.86e-05	CcSEcCtD
Esomeprazole—Abdominal pain—Epirubicin—hematologic cancer	5.41e-06	3.86e-05	CcSEcCtD
Esomeprazole—Body temperature increased—Epirubicin—hematologic cancer	5.41e-06	3.86e-05	CcSEcCtD
Esomeprazole—Hypersensitivity—Methotrexate—hematologic cancer	5.39e-06	3.84e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—IDH2—hematologic cancer	5.29e-06	0.000319	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—HMMR—hematologic cancer	5.29e-06	0.000319	CbGpPWpGaD
Esomeprazole—Asthenia—Methotrexate—hematologic cancer	5.25e-06	3.74e-05	CcSEcCtD
Esomeprazole—Feeling abnormal—Doxorubicin—hematologic cancer	5.22e-06	3.72e-05	CcSEcCtD
Esomeprazole—CYP3A4—Metabolism—DCK—hematologic cancer	5.2e-06	0.000314	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—B3GAT1—hematologic cancer	5.2e-06	0.000314	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ASNS—hematologic cancer	5.2e-06	0.000314	CbGpPWpGaD
Esomeprazole—Nausea—Prednisone—hematologic cancer	5.2e-06	3.7e-05	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Doxorubicin—hematologic cancer	5.18e-06	3.69e-05	CcSEcCtD
Esomeprazole—Pruritus—Methotrexate—hematologic cancer	5.17e-06	3.69e-05	CcSEcCtD
Esomeprazole—Hypersensitivity—Epirubicin—hematologic cancer	5.04e-06	3.59e-05	CcSEcCtD
Esomeprazole—Urticaria—Doxorubicin—hematologic cancer	5.03e-06	3.58e-05	CcSEcCtD
Esomeprazole—Abdominal pain—Doxorubicin—hematologic cancer	5e-06	3.57e-05	CcSEcCtD
Esomeprazole—Body temperature increased—Doxorubicin—hematologic cancer	5e-06	3.57e-05	CcSEcCtD
Esomeprazole—Diarrhoea—Methotrexate—hematologic cancer	5e-06	3.57e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	4.98e-06	0.000301	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ARNTL—hematologic cancer	4.97e-06	0.0003	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—HDC—hematologic cancer	4.93e-06	0.000297	CbGpPWpGaD
Esomeprazole—Asthenia—Epirubicin—hematologic cancer	4.91e-06	3.5e-05	CcSEcCtD
Esomeprazole—Pruritus—Epirubicin—hematologic cancer	4.84e-06	3.45e-05	CcSEcCtD
Esomeprazole—Dizziness—Methotrexate—hematologic cancer	4.83e-06	3.45e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—ACP5—hematologic cancer	4.83e-06	0.000292	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CA9—hematologic cancer	4.83e-06	0.000292	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—NCOR2—hematologic cancer	4.77e-06	0.000288	CbGpPWpGaD
Esomeprazole—Diarrhoea—Epirubicin—hematologic cancer	4.68e-06	3.34e-05	CcSEcCtD
Esomeprazole—Hypersensitivity—Doxorubicin—hematologic cancer	4.66e-06	3.32e-05	CcSEcCtD
Esomeprazole—Vomiting—Methotrexate—hematologic cancer	4.65e-06	3.31e-05	CcSEcCtD
Esomeprazole—Rash—Methotrexate—hematologic cancer	4.61e-06	3.29e-05	CcSEcCtD
Esomeprazole—Dermatitis—Methotrexate—hematologic cancer	4.61e-06	3.28e-05	CcSEcCtD
Esomeprazole—Headache—Methotrexate—hematologic cancer	4.58e-06	3.26e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—IDH1—hematologic cancer	4.55e-06	0.000274	CbGpPWpGaD
Esomeprazole—Asthenia—Doxorubicin—hematologic cancer	4.54e-06	3.24e-05	CcSEcCtD
Esomeprazole—Dizziness—Epirubicin—hematologic cancer	4.52e-06	3.22e-05	CcSEcCtD
Esomeprazole—CYP3A4—Metabolism—CDA—hematologic cancer	4.51e-06	0.000272	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ABCC3—hematologic cancer	4.49e-06	0.000271	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—TXN—hematologic cancer	4.49e-06	0.000271	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTO1—hematologic cancer	4.49e-06	0.000271	CbGpPWpGaD
Esomeprazole—Pruritus—Doxorubicin—hematologic cancer	4.48e-06	3.19e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—SPHK1—hematologic cancer	4.4e-06	0.000265	CbGpPWpGaD
Esomeprazole—Vomiting—Epirubicin—hematologic cancer	4.35e-06	3.1e-05	CcSEcCtD
Esomeprazole—Nausea—Methotrexate—hematologic cancer	4.34e-06	3.1e-05	CcSEcCtD
Esomeprazole—CYP3A4—Metabolism—PC—hematologic cancer	4.34e-06	0.000262	CbGpPWpGaD
Esomeprazole—Diarrhoea—Doxorubicin—hematologic cancer	4.33e-06	3.09e-05	CcSEcCtD
Esomeprazole—Rash—Epirubicin—hematologic cancer	4.31e-06	3.07e-05	CcSEcCtD
Esomeprazole—Dermatitis—Epirubicin—hematologic cancer	4.31e-06	3.07e-05	CcSEcCtD
Esomeprazole—Headache—Epirubicin—hematologic cancer	4.29e-06	3.06e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—UGT1A1—hematologic cancer	4.23e-06	0.000255	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GBA—hematologic cancer	4.19e-06	0.000253	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—SLC35B2—hematologic cancer	4.19e-06	0.000253	CbGpPWpGaD
Esomeprazole—Dizziness—Doxorubicin—hematologic cancer	4.19e-06	2.98e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—SLC22A1—hematologic cancer	4.11e-06	0.000248	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CRABP1—hematologic cancer	4.11e-06	0.000248	CbGpPWpGaD
Esomeprazole—Nausea—Epirubicin—hematologic cancer	4.06e-06	2.9e-05	CcSEcCtD
Esomeprazole—Vomiting—Doxorubicin—hematologic cancer	4.03e-06	2.87e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—ALOX5—hematologic cancer	4.01e-06	0.000242	CbGpPWpGaD
Esomeprazole—Rash—Doxorubicin—hematologic cancer	3.99e-06	2.85e-05	CcSEcCtD
Esomeprazole—Dermatitis—Doxorubicin—hematologic cancer	3.99e-06	2.84e-05	CcSEcCtD
Esomeprazole—Headache—Doxorubicin—hematologic cancer	3.97e-06	2.83e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—NUP98—hematologic cancer	3.88e-06	0.000234	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—MTAP—hematologic cancer	3.84e-06	0.000231	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—NCOA3—hematologic cancer	3.77e-06	0.000227	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ADCY7—hematologic cancer	3.77e-06	0.000227	CbGpPWpGaD
Esomeprazole—Nausea—Doxorubicin—hematologic cancer	3.76e-06	2.68e-05	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—NUP214—hematologic cancer	3.74e-06	0.000226	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.7e-06	0.000223	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ABCG2—hematologic cancer	3.66e-06	0.000221	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—MTR—hematologic cancer	3.66e-06	0.000221	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ENO2—hematologic cancer	3.59e-06	0.000217	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTT1—hematologic cancer	3.48e-06	0.00021	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.43e-06	0.000207	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—FHL2—hematologic cancer	3.42e-06	0.000206	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—SDC1—hematologic cancer	3.41e-06	0.000205	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—AGRN—hematologic cancer	3.35e-06	0.000202	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.25e-06	0.000196	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.21e-06	0.000194	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—HMMR—hematologic cancer	3.18e-06	0.000192	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—IDH2—hematologic cancer	3.18e-06	0.000192	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.07e-06	0.000185	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ARNTL—hematologic cancer	2.99e-06	0.00018	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CA9—hematologic cancer	2.91e-06	0.000175	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ACP5—hematologic cancer	2.91e-06	0.000175	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CD44—hematologic cancer	2.9e-06	0.000175	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—NQO1—hematologic cancer	2.9e-06	0.000175	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—NCOR2—hematologic cancer	2.87e-06	0.000173	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.84e-06	0.000171	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CYCS—hematologic cancer	2.74e-06	0.000165	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—IDH1—hematologic cancer	2.73e-06	0.000165	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	2.72e-06	0.000164	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTO1—hematologic cancer	2.7e-06	0.000163	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ABCC3—hematologic cancer	2.7e-06	0.000163	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—TXN—hematologic cancer	2.7e-06	0.000163	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—SPHK1—hematologic cancer	2.64e-06	0.000159	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—UGT1A1—hematologic cancer	2.54e-06	0.000153	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—SLC22A1—hematologic cancer	2.47e-06	0.000149	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CRABP1—hematologic cancer	2.47e-06	0.000149	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.45e-06	0.000148	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTP1—hematologic cancer	2.42e-06	0.000146	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.41e-06	0.000145	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.34e-06	0.000141	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—NUP98—hematologic cancer	2.33e-06	0.000141	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ABCB1—hematologic cancer	2.29e-06	0.000138	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.26e-06	0.000137	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.26e-06	0.000137	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—NUP214—hematologic cancer	2.25e-06	0.000136	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—NCOR1—hematologic cancer	2.22e-06	0.000134	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTM1—hematologic cancer	2.22e-06	0.000134	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—MTR—hematologic cancer	2.2e-06	0.000133	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.2e-06	0.000133	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ENO2—hematologic cancer	2.16e-06	0.00013	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.1e-06	0.000126	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—SDC1—hematologic cancer	2.05e-06	0.000124	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.96e-06	0.000118	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CD44—hematologic cancer	1.74e-06	0.000105	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—NQO1—hematologic cancer	1.74e-06	0.000105	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.73e-06	0.000104	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.65e-06	9.94e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CYCS—hematologic cancer	1.65e-06	9.94e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.64e-06	9.87e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.53e-06	9.22e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.45e-06	8.76e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.45e-06	8.74e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ALB—hematologic cancer	1.43e-06	8.63e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.37e-06	8.29e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.37e-06	8.25e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.33e-06	8.05e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.33e-06	8.05e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.26e-06	7.62e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.18e-06	7.11e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PTEN—hematologic cancer	1.09e-06	6.58e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—EP300—hematologic cancer	1.04e-06	6.28e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3CG—hematologic cancer	9.91e-07	5.98e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CREBBP—hematologic cancer	9.19e-07	5.54e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3CD—hematologic cancer	8.71e-07	5.25e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ALB—hematologic cancer	8.6e-07	5.19e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3R1—hematologic cancer	8.23e-07	4.96e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3CA—hematologic cancer	7.7e-07	4.64e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3CB—hematologic cancer	7.59e-07	4.58e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PTEN—hematologic cancer	6.56e-07	3.96e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—AKT1—hematologic cancer	6.29e-07	3.79e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—EP300—hematologic cancer	6.26e-07	3.77e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4.63e-07	2.79e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—AKT1—hematologic cancer	3.78e-07	2.28e-05	CbGpPWpGaD
